BackAlzex Neuropharma Overview
Alzex Neuropharma Inc.

Alzex Neuropharma Return on Equity

Valuation check: TRRI's ROE is 45.41%, above the sector sector average of 10.27%.

Get informed when a big investor buys or sells

+ Follow

ROE

45.41%

Return on Equity

45.41%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Alzex Neuropharma (TRRI) FAQ

The latest ROE for TRRI is 45.41%. That is above the sector sector average of 10.27%. Investors often review this figure alongside Alzex Neuropharma's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, TRRI currently prints 45.41% for ROE, while the sector average sits near 10.27%. That is roughly 342.4% above the sector mean. Large gaps often invite a closer look at Alzex Neuropharma's growth, margins, and balance sheet.

Return on Equity shows how effectively Alzex Neuropharma converts resources into returns. At 45.41%, TRRI may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TRRI's ROE (45.41%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers